跳至主要内容
临床试验/CTRI/2016/04/006873
CTRI/2016/04/006873已完成2 期

Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Surgeryâ?? A prospective randomized controlled study - RIGoROCS

Tata Medical center Kolkata0 个研究点目标入组 144 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
144

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Cytoreductive surgery for ovarian cancer-
  • PDS: primary (chemo-naïve patients including completion staging/ primary debulking and secondary cytoreduction)
  • IDS: interval debulking surgery (after chemotherapy)
  • -American Society of Anesthesiology (ASA-PS) score of 1 â?? 3
  • -Age more than 18 years and less than 65 years
  • -Surgery of duration more than 240 minutes
  • -Presumed blood loss more than 500 ml
  • -Elective surgery

排除标准

  • -Patient refusal
  • -Inability to give consent
  • -Laparoscopic surgery, Emergency surgery, patients undergoing HIPEC
  • -Age younger than 18 years & more than 65 yrs, BMI > 40
  • -Patients with LVEF < 30%, Arrhythmia, Acute MI (within 30 days)
  • -COPD with FEV1 < 50%
  • -Coagulopathy (platelet <50000/μL, aPTT > x2 control, INR >1.5)
  • -Significant liver dysfunction (liver enzymes >x3 times normal)
  • -Significant renal dysfunction (creatinine >x2 times normal)
  • -Psychiatric disorders
  • -Sepsis or SIRS
  • -Hypersensitivity to Gelofusine

研究者

发起方
Tata Medical center Kolkata

相似试验